Clinical trials: sponsored by Centre Leon Berard
Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST)
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments
This trial is a prospective, randomized (1:1 ratio), multicenter, comparative and phase II study, conducted in patients with unresectable advanced gastrointestinal stromal tumors (GIST) after failure of imatinib (disease…
- Conditions
- Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor
- Trial name
- ATEZOGIST (NCT05152472)
- Testing
- Atezolizumab 1200 mg, Imatinib 400 MG
- Where
- 13 sites in France
- Volunteers
- 58 people
- Sponsor
- Centre Leon Berard
Head & Neck Cancer
Radiotherapy In a Sitting Position for Enhanced Reproducibility
Qualitative, longitudinal and single-center study To explore the reproductibility and the acceptability of the sitting position for head and neck cancer patients through their experience of sitting and supine positions in the…
- Trial name
- RISE R (NCT07887048)
- Testing
- Simulation of radiotherapy session in sitting position
- Volunteers
- 16 people
- Sponsor
- Centre Leon Berard
Gastro Oesophageal Cancer
Biomarker Investigation for Early Gastric Cancer Detection
GASTROTRACK is a prospective, single-center clinico-biological cohort study evaluating non-invasive biomarkers for gastric and gastroesophageal junction adenocarcinomas (GEC).
- Trial name
- GASTROTRACK (NCT07884669)
- Testing
- Saliva sampling, Gastric juice sampling, Blood sampling
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Centre Leon Berard
Breast Cancer, Medico-economic Impact
Preoperative Magnetic Tracking in Breast Surgery in France: French Medical-economic Study.
MAGNETO is a French medico-economic study on preoperative localization in breast cancer surgery. The main objective is to conduct a cost-consequence analysis comparing magnetic clip localization with the use of metallic wires for…
- Conditions
- Breast Cancer, Medico-economic Impact, Breast Cancer Surgery
- Trial name
- MAGNETO (NCT06906601)
- Testing
- magnetic clip localization, metallic wire localization., Breast cancer surgery
- Where
- 7 sites in France
- Volunteers
- 772 people
- Sponsor
- Centre Leon Berard
Vulvar Squamous Cell Carcinoma
Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma Patients
COLOMBE is a multicenter, single arm, phase 1/2 trial designed to evaluate the safety and efficacy of imiquimod cream with IV low dose nivolumab in primary resectable vulvar squamous cell carcinoma patients prior to surgery…
- Trial name
- COLOMBE (NCT07679841)
- Testing
- Imiquimod 5% cream, Nivolumab
- Where
- 11 sites in France
- Volunteers
- 50 people
- Sponsor
- Centre Leon Berard
Advanced Solid Tumors, Metastatic Solid Tumors
NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies
This study is a multicenter, open-label, proof-of-concept study aiming to assess the clinical and biological impact of NP137 when added to standard PD-1/PD-L1 blockade therapy in 3 independent cohorts of advanced or metastatic…
- Trial name
- IMMUNONET (NCT05605496)
- Testing
- NP137, anti-PD-1/PD-L1
- Where
- 5 sites in France
- Volunteers
- 57 people
- Sponsor
- Centre Leon Berard
Metastatic Clear Cell Renal Cell Carcinoma
Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal Cell Carcinoma
This study is an open label, Phase I study investigating the safety and clinical activity of 4 IV injections of 161Tb-PSMA-1 in patients with mccRCC.
- Trial name
- PRadR2 (NCT07828249)
- Testing
- 161Tb-PSMA-1 (radiopharmaceutical)
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Centre Leon Berard
Re-irradiation, Radiotherapy
Contribution of Multicenter Expertise and Deformable Fusion Software for Re-irradiations With Curative Intent
We propose to evaluate the contribution of a standardized process combining, a validation of re-irradiation indications by a group of multi-professional experts (radiotherapists and physicists) and, a collective validation of the…
- Trial name
- ADERE (NCT06668038)
- Testing
- Multidisciplinary and multicenter validation of re-irradiation with curative intent
- Where
- 10 sites in France
- Volunteers
- 100 people
- Sponsor
- Centre Leon Berard
Seminoma, Stage II
De-escalation Study for Stage IIa/IIb < 3 cm Seminoma
Phase II, multicenter, prospective, randomized, non-comparative, de-escalation study. Patients with stage IIa/IIb < 3 cm seminoma histologically proved after orchiectomy will be included in the study and will receive 1 cycle of…
- Trial name
- EDEN (NCT05529251)
- Testing
- Radiotherapy boost, Carboplatin AUC7, 3 cycles of EP
- Where
- 15 sites in France
- Volunteers
- 90 people
- Sponsor
- Centre Leon Berard
Glioma, CNS Tumor, Adult
Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
This clinical trial is a 2-phase trial designed to evaluate the safety of tarlatamab in combination with a fixed dose of metronomic temozolomide in adolescents and adults with CNS tumors (stratified into two age-based cohorts)…
- Conditions
- Glioma, CNS Tumor, Adult, CNS Tumor, Childhood
- Trial name
- TARLATEM (NCT07243470)
- Testing
- Tarlatamab, Temozolomide (TMZ)
- Where
- 12 sites in France
- Volunteers
- 70 people
- Sponsor
- Centre Leon Berard
Non-Resectable Pancreas Carcinoma
Evaluation of the High Intensity Focused Ultrasound (HIFU) Technique for Patients With Unresectable Pancreatic Tumor Treatment (PULS)
This is a phase I/II, multicenter trial for patients with locally advanced and unresectable pancreatic tumours : A Phase I evaluating the tolerance of intraoperative High Intensity Focused Ultrasound (HIFU) intervention on the…
- Trial name
- PULS (NCT06211933)
- Testing
- HIFU intervention
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Centre Leon Berard
Localized Resectable Tumor, MSI/dMMR
Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.
This trial is a multicenter, 3-cohort, prospective, Phase II trial conducted in patients with untreated resectable MSI/dMMR carcinomas and aiming to evaluate the safety and the efficacy of ICI (immune checkpoint inhibitor) as…
- Trial name
- IMHOTEP (NCT04795661)
- Testing
- Pembrolizumab
- Where
- 18 sites in France
- Volunteers
- 240 people
- Sponsor
- Centre Leon Berard
Gastric Cancers
R-GASTIM- Study of Gastric Cancer Operable
Clinicobiological cohort of gastric cancers operated in our institution.
- Trial name
- R-GASTIM (NCT07787052)
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Centre Leon Berard
Lung Neoplasms, Non Small Cell Lung Cancer
ERICA-02 Study : Impact of Physical Exercise on the Tumor Immune Microenvironment in Patients Treated With Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer
Recent advances combining chemotherapy and immunotherapy before surgery have significantly improved outcomes for patients with resectable non-small cell lung cancer (NSCLC).
- Trial name
- ERICA-02 (NCT07786909)
- Testing
- Physical activity recommendations, Physical Activity (PA) Intervention
- Where
- 2 sites in France
- Volunteers
- 40 people
- Sponsor
- Centre Leon Berard
Malignant Solid Neoplasms
Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment
The MOST Plus study is a two-period phase II clinical trial, conducted in patients with all types of progressive solid tumors after at least 1 prior systemic treatment regimen for advanced disease (in the absence of a validated…
- Trial name
- MOST plus (NCT02029001)
- Testing
- Nilotinib (400 mg BID), Everolimus (10 mg QD), Sorafenib (400 mg BID)
- Where
- 7 sites in France
- Volunteers
- 900 people
- Sponsor
- Centre Leon Berard
Malignant Solid Tumor
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
This trial is a multicenter, open-label, biology driven, phase II study using a sequential Bayesian design, aiming to assess the efficacy and safety of different Matched Targeted Therapy (MTT) in independent and parallel cohorts…
- Trial name
- MegaMOST (NCT04116541)
- Testing
- HDM201, Ribociclib, Cabozantinib
- Where
- 13 sites in France
- Volunteers
- 455 people
- Sponsor
- Centre Leon Berard
Thyroid Carcinoma
Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
The objective of this study is to determine the feasibility of pazopanib treatment interruption with reintroduction at progression in iodine refractory progressive Differentiated Thyroid Cancer (DTC) patients as compared to…
- Trial name
- NCT01813136
- Testing
- Continuous pazopanib (Arm A), Intermittent pazopanib (Arm B)
- Where
- 13 sites in France
- Volunteers
- 168 people
- Sponsor
- Centre Leon Berard
Gastric Cancer, MSI-H
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
CIME is a multicenter, randomised, comparative, open-label phase III study aiming to compare the survival of patients suffering from MSI-H/dMMR locally advanced or metastatic oeasogastric adenocarcinoma treated by a…
- Conditions
- Gastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer
- Trial name
- CIME (NCT06346197)
- Testing
- Balstilimab, Botensilimab, Folfox Protocol
- Where
- 7 sites in France
- Volunteers
- 132 people
- Sponsor
- Centre Leon Berard
Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma
HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas
This trial is a two-step Phase I/II study comprising: Part 1: A dose escalation part with the aim to assess the safety of the proposed combination (N= up to 30 patients).
- Trial name
- AMPHISARC (NCT05180695)
- Testing
- Pazopanib, HDM201
- Where
- 5 sites in France
- Volunteers
- 47 people
- Sponsor
- Centre Leon Berard
Multiple Myeloma, Complication
PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.
This is a prospective, multicentre, phase III, randomised, controlled intervention study. Two groups of patients with equal numbers will be studied and each patient will be allocated to one of the two groups described below by…
- Trial name
- PASCA -MM (NCT05947136)
- Testing
- Interpretation of the results from the detection visit, Explaining detection results and referrals to the patient, Early medical care through the network
- Where
- 6 sites in France
- Volunteers
- 204 people
- Sponsor
- Centre Leon Berard